Truist Securities Reiterates Hold on Fate Therapeutics, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Hold' rating on Fate Therapeutics (NASDAQ:FATE) and maintained a price target of $7.
August 16, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has reiterated a 'Hold' rating on Fate Therapeutics and maintained a price target of $7.
The news is directly about Fate Therapeutics and its rating by Truist Securities. The 'Hold' rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target of $7 also indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100